Prognostic Significance of The Cereblon Expression in Multiple Myeloma Patients

Conclusion CRBN expression is of prognostic value in MM patients ineligible for ASCT treated with thalidomide as immunomodulatory drug. Indicating possible suboptimal treatment outcome, the level of CRBN expression may serve as additional prognostic tool in personalized treatment approach. Teaser Within a personalized treatment approach in multiple myeloma (MM), prognostic significance of the cereblon (CRBN) expression was analysed in 92 newly diagnosed patients. In patients treated with thalidomide based combinations, CRBN expression significantly affected treatment response (p=0.028), and progression free survival (PFS, p=0.017). Implicating treatment outcome, the level of CRBN expression may represent additional prognostic tool in personalized treatment approach.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research